Skip to main content
OpenTrials
Completed

NCT Number: NCT06074302

Hyaluronic Filler for Improvement of Radial Cheek Lines

Appearance of superficial radial cheek lines and fine lines of the cheek are signs of photoaging. These lines appear in a curvilinear or crosshatched fashion on the lower cheeks in photoaged individuals. They represent a common concern among patients seeking cosmetic treatments. With the aging population and increasing social awareness of cosmetic treatments, it is likely that the demand for filler procedures will increase. Current treatment options for these lines include fractionated and fully ablative laser resurfacing, topical retinoids, intradermal filler injections, and chemical peels.

One potential treatment for facial fine lines include use of low G' hyaluronic acid fillers, which allow for dynamic movement while also addressing the appearance of the lines. Resilient Hyaluronic Acid (RHA) Redensity is an FDA-cleared filler used for treatment of dynamic perioral rhytids. Hyaluronic acid-based fillers have been shown to improve overall skin texture (skin surface hydration, roughness, and elasticity) through the hypothesized mechanism of inducing a fibroblast response to boost collagen production. They have the potential to reduce appearance of facial fine lines of the cheek. This study will evaluate the efficacy of RHA Redensity in improving radial cheek lines.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aging

Age range

31 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Main Line Center for Laser Surgery

Ardmore, Pennsylvania, 19003, United States

About this study

This clinical investigation is a prospective study consisting of a 2 treatment visits and a follow-up visit. A total of 20 patients will be recruited.

Treatment Plan Screening Visit and Treatment Visit 1 A total of 20 patients with facial fine lines of the cheeks/radial cheek lines will be treated with Resilient Hyaluronic Acid (RHA) Redensity, off-label. Patients will be consented, photographed with the Canfield Visia, and be asked to fill out the Facial Appearance, Health-Related Quality of Life and Adverse Effects (FACE-Q) Appraisal of Lines: Overall and FACE-Q Age Appraisal Visual Analog Scale surveys. The physician will fill out the Allergan Fine Lines Scale.

After discussion with the patient, volume of filler needed will be determined at the discretion of the provider, up to 2cc per cheek. RHA Redensity will be applied using a microdroplet technique, with approximately 0.02-0.04cc of product injected sub-dermally approximately 0.5-1cm apart on the malar and nasolabial cheek. The boundaries of the injection area will be defined by the nasolabial fold, nasojugal groove, palpebromalar groove, mandible, and preauricular crease. After treatment, the area will be lightly massaged by the physician. The patient will be asked to ice the area 3 times daily for 24 hours and post-op instructions will be provided.

Treatment Visit 2 (4 weeks +/- 2 weeks) Photographs using the Canfield Visia will be taken. Patients will return for a repeat treatment of RHA Redensity of the cheek using the microdroplet technique as described above. A maximum of 2cc will be used per cheek.

Follow-up visit (8 weeks +/-2 weeks) Patients will be photographed and will be asked to fill out the FACE-Q Appraisal of Lines: Overall and FACE-Q Age Appraisal Visual Analog Scale surveys. The physician will fill out the Allergan Fine Lines Scale. The patient will fill out the FACE-Q Appraisal of Lines: Overall and FACE-Q Age Appraisal Visual Analog Scale surveys. Photographs of the patient will be captured using the Canfield Visia camera.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 31 years old or great
  • Rating of 2, 3, or 4 on 5-point Allergan Fine Lines Scale on the cheeks

Exclusion criteria

  • Pregnancy
  • Prior adverse reaction to hyaluronic acid treatment (injectable or over-the-counter topical)
  • Connective tissue disorder
  • Active infection in treatment area
  • Active severe inflammatory disease in treatment area such as atopic dermatitis, psoriasis
  • Treatment with toxin or filler in lower face below the orbital rim within the past 6 months

Treatment and study plan

RHA Redensity

Device

RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.

Primary outcomes

  1. Allergan Fine Lines Scale

    Time frame: 10 weeks

    1-point improvement of facial fine lines of the cheek based on the validated Allergan Fine Lines Scale between baseline and 8-week follow-up. Scale is a 5-point scale rated from 0 to 4, with 0 representing no fine lines and 4 representing diffuse fine lines with cross-hatching.

Secondary outcomes

  1. FACE-Q Appraisal of Lines: Overall

    Time frame: 10 weeks

    Improvement in scores in patient-reported outcomes based on the validated FACE-Q Appraisal of Lines: Overall between baseline and 8-week follow-up. Scale is scored on a 1-100 scale, with 100 representing excellent quality of life with regards to facial fine lines.

Sponsors and collaborators

Lead sponsor

Main Line Center for Laser Surgery

Other

Registry information

Official study title

Use of a Hyaluronic Acid Filler (Resilient Hyaluronic Acid [RHA] Redensity) for Improvement of Radial Cheek Lines

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 10, 2023
Registry last updated
Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.